TY - JOUR
T1 - Contrast-Enhanced Ultrasound (CEUS) for the Diagnosis and Management of Hepatocellular Carcinoma
T2 - Current Status and Future Trends
AU - Malone, Christopher D.
AU - Mattrey, Robert F.
AU - Fetzer, David T.
N1 - Publisher Copyright:
© Springer Science+Business Media New York 2016.
PY - 2016/12
Y1 - 2016/12
N2 - Purpose of Review: This review discusses the use of contrast-enhanced ultrasound (CEUS) for liver lesion detection and characterization focusing on hepatocellular carcinoma (HCC). It reviews the uses of CEUS in managing patients with HCC, such as in image-guided intervention, assessment of tumor viability after locoregional treatment, and differentiation of bland from tumor thrombus. Finally, it highlights potential future uses of microbubbles in targeted HCC detection and drug delivery. Recent Findings: The high temporal resolution of ultrasound relative to CT and MRI and its sensitivity to microbubbles enables precise analysis of enhancement profiles at miniscule contrast doses, enabling confident diagnosis of HCC and differentiation of HCC from other benign and malignant hepatic lesions. Summary: CEUS has gained widespread acceptance worldwide for the diagnosis and management of patients with HCC. CEUS is poised to make a large clinical impact in the USA given the recent Food and Drug Administration approval of a CEUS agent for use in liver imaging.
AB - Purpose of Review: This review discusses the use of contrast-enhanced ultrasound (CEUS) for liver lesion detection and characterization focusing on hepatocellular carcinoma (HCC). It reviews the uses of CEUS in managing patients with HCC, such as in image-guided intervention, assessment of tumor viability after locoregional treatment, and differentiation of bland from tumor thrombus. Finally, it highlights potential future uses of microbubbles in targeted HCC detection and drug delivery. Recent Findings: The high temporal resolution of ultrasound relative to CT and MRI and its sensitivity to microbubbles enables precise analysis of enhancement profiles at miniscule contrast doses, enabling confident diagnosis of HCC and differentiation of HCC from other benign and malignant hepatic lesions. Summary: CEUS has gained widespread acceptance worldwide for the diagnosis and management of patients with HCC. CEUS is poised to make a large clinical impact in the USA given the recent Food and Drug Administration approval of a CEUS agent for use in liver imaging.
KW - CEUS
KW - Contrast agents
KW - Contrast-enhanced ultrasound
KW - HCC
KW - Hepatocellular carcinoma
KW - Microbubbles
KW - Tumor thrombus
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85080976479&partnerID=8YFLogxK
U2 - 10.1007/s11901-016-0324-8
DO - 10.1007/s11901-016-0324-8
M3 - Article
AN - SCOPUS:85080976479
SN - 2195-9595
VL - 15
SP - 307
EP - 316
JO - Current Hepatology Reports
JF - Current Hepatology Reports
IS - 4
ER -